Key Performance
More- Earnings Score: N/A
- Momentum Score: 68
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Over 25 pharmaceutical companies are advancing 30+ pipeline drugs for myasthenia gravis treatment, with approximately 5+ therapies in late-stage development. Key players including Immunovant, Cartesian Therapeutics, Novartis, and others are developing promising therapies using novel mechanisms of action such as IgG degraders and complement inhibitors. Recent developments include positive Phase III trial results and regulatory approvals for multiple candidates.
06/02/2026, 1:00 PM • GlobeNewswire
The myasthenia gravis market is projected to grow from USD 6 billion in 2025 to over USD 16 billion by 2036, driven by rising diagnosed prevalence, improved diagnostics, and an expanding pipeline of targeted biologic therapies including FcRn inhibitors, complement inhibitors, and CAR-T cell therapies. The market is currently led by argenx and UCB, with numerous emerging candidates in late-stage development expected to significantly accelerate growth.
05/18/2026, 1:00 PM • GlobeNewswire
The Crohn's Disease therapeutics market across eight major markets is projected to grow from $9.5 billion to $13.8 billion by 2032 at a CAGR of 3.9%, driven by approvals of 8 pipeline, generic, and biosimilar therapies. Novel mechanisms of action and emerging treatments will reshape the competitive landscape, with key opportunities in strategic licensing and partnerships.
04/10/2026, 4:43 AM • GlobeNewswire
UCB - Convocation à l'assemblée générale des actionnaires 2026
UCB SA convenes its General Shareholders Meeting for April 30, 2026, to approve 2025 annual accounts, a dividend of €1.45 per share, and renew mandates for CEO Jean-Christophe Tellier and administrator Cédric van Rijckevorsel. The meeting will also address capital authorization renewal, share buyback authorization up to 10%, and approval of EMTN program change-of-control clauses.
03/27/2026, 2:00 AM • GlobeNewswire
UCB - Convening Notice to the General Meeting of the Shareholders 2026
UCB SA/NV has issued a convening notice for its General Meeting of Shareholders scheduled for April 30, 2026, in Brussels. The agenda includes approval of 2025 annual accounts with a proposed dividend of €1.45 per share, renewal of director mandates for Jean-Christophe Tellier (CEO) and Cédric van Rijckevorsel, and authorization renewals for the Board of Directors regarding authorized capital and share buybacks. The meeting will also address approval of change of control provisions in the EMTN Program.
03/27/2026, 2:00 AM • GlobeNewswire
UCB - Oproeping tot de algemene vergadering van aandeelhouders 2026
UCB NV announces its General Shareholders Meeting scheduled for April 30, 2026, covering routine matters including approval of 2025 financial statements, dividend distribution of €1.45 per share, renewal of board mandates for CEO Jean-Christophe Tellier and director Cédric van Rijckevorsel, and approval of control change clauses in the EMTN program. The extraordinary session will address renewal of board authorization for capital increases and share buyback programs.
03/27/2026, 2:00 AM • GlobeNewswire
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment
Johnson & Johnson announced positive Phase 2b results for nipocalimab, an experimental FcRn blocker for treating systemic lupus erythematosus (SLE). The JASMINE study of 228 subjects met its primary endpoint and key secondary endpoints, with a favorable safety profile. The company plans to initiate Phase 3 trials. The lupus treatment market includes competing programs from UCB/Biogen, Cartesian Therapeutics, and Adicet Bio.
01/06/2026, 1:42 PM • Benzinga
A class action lawsuit has been filed against MoonLake Immunotherapeutics alleging misleading investors about its drug candidate sonelokimab, which failed to demonstrate superiority in Phase 3 trials, causing the stock to plummet 89.9%.
12/13/2025, 9:21 AM • GlobeNewswire
A class action lawsuit has been filed against MoonLake Immunotherapeutics alleging misleading investors about its drug candidate sonelokimab, which failed to demonstrate superiority in Phase 3 trials, causing the stock to plummet by nearly 90%.
12/10/2025, 6:14 PM • GlobeNewswire
Financière de Tubize strengthens its expertise in the biopharma field by appointing 2 new directors
UCB's Board of Directors appointed two new directors, Iris Löw-Friedrich and Carinne Brouillon, to enhance biopharma expertise. Bruno Holthof highlighted the strategic importance of these appointments, and Cyril Janssen was named Vice-President to manage family shareholder relations.
09/24/2025, 10:00 AM • GlobeNewswire
Financière de Tubize appointed two new board directors, Iris Löw-Friedrich and Carinne Brouillon, to enhance its biopharmaceutical expertise and support UCB's strategic development.
09/24/2025, 10:00 AM • GlobeNewswire
La Financière de Tubize has appointed two new board members, Iris Löw-Friedrich and Carinne Brouillon, to enhance its biopharma expertise and support UCB's strategic development. Cyril Janssen was also named Vice-President to manage shareholder relations.
09/24/2025, 10:00 AM • GlobeNewswire
Financière de Tubize - 2025 half-year financial report
Financière de Tubize reported a 2.8% increase in first-half 2025 profits, received €98.1 million in dividends from UCB, paid €46.3 million in dividends to shareholders, and increased its UCB stake to 36.28% while eliminating bank borrowings.
08/02/2025, 2:00 AM • GlobeNewswire
Financière de Tubize - Halfjaarlijks verslag 2025
Financière de Tubize reports a 2.8% increase in semester profit to €95.6 million, received €98.1 million in dividends from UCB, and reduced bank debt to zero by mid-2025.
08/02/2025, 2:00 AM • GlobeNewswire
Financière de Tubize - Rapport financier semestriel 2025
Financière de Tubize reports a 2.8% increase in first-half 2025 profits, receiving €98.1 million in dividends from UCB and paying €46.3 million to its own shareholders. The company also reduced its bank debt to zero and slightly increased its UCB shareholding.
08/02/2025, 2:00 AM • GlobeNewswire